Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer.
Recently, the National Surgical Adjuvant Study of Colorectal Cancer in Japan, a randomised controlled trial of oral uracil-tegafur (UFT) adjuvant therapy for stage III rectal cancer, showed remarkable survival gains, compared with surgery alone. To evaluate value for money of adjuvant UFT therapy, cost-effective analysis was carried out. Cost-effectiveness analysis of adjuvant UFT therapy was carried out from a payer's perspective, compared with surgery alone. Overall survival and relapse-free survival were estimated by Kaplan-Meier method, up to 5.6 years from randomisation. Costs were estimated from trial data during observation. Quality-adjusted life-years (QALYs) were calculated using utility score from literature. Beyond observation period, they were simulated by the Boag model combined with the competing risk model. For 5.6-year observation, 10-year follow-up and over lifetime, adjuvant UFT therapy gained 0.50, 0.96 and 2.28 QALYs, and reduced costs by $2457, $1771 and $1843 per person compared with surgery alone, respectively (3% discount rate for both effect and costs). Cost-effectiveness acceptability and net monetary benefit analyses showed the robustness of these results. Economic evaluation of adjuvant UFT therapy showed that this therapy is cost saving and can be considered as a cost-effective treatment universally accepted for wide use in Japan.
Hisashige
A
A
The Institute of Healthcare Technology Assessment, Tokushima 770-0044, Japan. akih@k3.dion.ne.jp
Yoshida
S
S
Kodaira
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics*; D017024:Chemotherapy, Adjuvant / Q000191:economics; D003362:Cost-Benefit Analysis; D013505:Digestive System Surgical Procedures; D005260:Female; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D019057:Quality-Adjusted Life Years; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000191:economics; D014498:Uracil / Q000008:administration & dosage / Q000191:economics
D005641:Tegafur; D014498:Uracil
N Engl J Med. 2004 Oct 21;351(17):1731-40
15496622
Lancet. 2001 Oct 20;358(9290):1291-304
11684209
Ann Oncol. 1997 Jan;8(1):65-70
9093709
Health Econ. 2004 May;13(5):429-36
15127423
Annu Rev Public Health. 1997;18:105-34
9143714
J Clin Oncol. 2005 Sep 1;23(25):6199-206
16135487
Med Decis Making. 2004 Mar-Apr;24(2):131-41
15090099
Br J Cancer. 2007 Feb 12;96(3):439-44
17245343
Pharmacoeconomics. 2007;25(7):537-62
17610336
N Engl J Med. 2004 Jun 3;350(23):2343-51
15175436
Br J Cancer. 2006 Jan 16;94(1):69-73
16404362
Jpn J Clin Oncol. 2006 Apr;36(4):191-2
16684858
J Clin Oncol. 2000 Sep 15;18(18):3302-17
10986064
Eur J Cancer. 2002 May;38(7):953-63
11978520
J Clin Oncol. 2006 May 1;24(13):2059-64
16648506
Eur J Gastroenterol Hepatol. 2004 Jun;16(6):551-61
15167156
J Natl Cancer Inst. 1988 Mar 2;80(1):21-9
3276900
Acta Oncol. 2001;40(2-3):282-308
11441937
Langenbecks Arch Surg. 1998 Dec;383(6):409-15
9921940
Surg Oncol. 2004 Aug-Nov;13(2-3):63-73
15572088
Cancer. 2007 Mar 15;109(6):1082-9
17265519
J Clin Oncol. 2004 Feb 1;22(3):484-92
14752071
Jpn J Clin Oncol. 1999 Feb;29(2):78-86
10089948
Pharmacoeconomics. 2001;19(6):609-21
11456210
N Engl J Med. 2005 Jun 30;352(26):2696-704
15987918
Langenbecks Arch Surg. 2002 Mar;386(8):575-81
11914933
Clin Gastroenterol Hepatol. 2006 Jul;4(7):808-21
16797250
Biometrics. 1997 Jun;53(2):419-34
9192444
Am J Gastroenterol. 1999 Jun;94(6):1650-7
10364039
JAMA. 2000 Aug 23-30;284(8):1008-15
10944647
Expert Rev Pharmacoecon Outcomes Res. 2001 Oct;1(1):25-36
19807505
Ann Surg Oncol. 2006 Aug;13(8):1021-34
16897272
Pharmacoeconomics. 2004;22 Suppl 4:5-10
15876007
Jpn J Clin Oncol. 2006 Apr;36(4):237-44
16675478
BMJ. 2005 Aug 20;331(7514):446-8
16110075
Pharmacoeconomics. 2005;23(7):639-49
16173156
N Engl J Med. 2001 Aug 30;345(9):638-46
11547717